

1642  
Docket No.: PF-0530-1 DIV

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Non-Fee Amendment, Commissioner for Patents, Washington, D.C. 20231 on July 26, 2002.

By: 

Printed: Margaret M. Hasson

COPY OF PAPERS  
ORIGINALLY FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: HUMAN GLUTATHIONE PEROXIDASE-6

Serial No.: 09/811,118

Filing Date: March 16, 2001

Examiner: Yaen, C.H.

Group Art Unit: 1642



Box Non-Fee Amendment  
Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard;
2. Response to Restriction Requirement (13 pp.); and
3. Limited Recognition Under 37 C.F.R. §10.9(b).

The fee has been calculated as shown below.

Claims	Claims After Amendment		Claims Previously Paid For		Present Extra	Other Than Small Entity Rate		Additional Fee(s)
Total	21	-	21		0	x\$18.00		\$ 0
Indept.	3	-	3		0	x\$84.00		\$ 0
First Presentation of Multiple Dependent Claims						+280.00		\$ 0
Total Fee:								\$ 0

X No additional Fee is required.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: July 26, 2002.

  
Terence P. Lo

Limited Recognition (37 C.F.R. 10.9 (b)) attached  
Direct Dial Telephone: (650) 621-8581

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166

98248

1

09/811,118

## Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Non-Fee Amendment, Commissioner for Patents, Washington, D.C. 20231 on July 26, 2002.

By: 

Printed: Margaret M. Hasson

COPY OF PAPER  
ORIGINALLY FILED

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: HUMAN GLUTATHIONE PEROXIDASE-6

Serial No.: 09/811,118

Filing Date: March 16, 2001

Examiner: Yaen, C.H.

Group Art Unit: 1642



Box Non-Fee Amendment  
Commissioner for Patents  
Washington, D.C. 20231

## TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard;
2. Response to Restriction Requirement (13 pp.); and
3. Limited Recognition Under 37 C.F.R. §10.9(b).

The fee has been calculated as shown below.

Claims	Claims After Amendment	-	Claims Previously Paid For	=	Present Extra	Other Than Small Entity Rate	Fee	Additional Fee(s)
Total	21	-	21		0	x\$18.00		\$ 0
Indept.	3	-	3		0	x\$84.00		\$ 0
First Presentation of Multiple Dependent Claims						+280.00		\$ 0
Total Fee:								\$ 0

☒ No additional Fee is required.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: July 26, 2002  
Terence P. Lo

Limited Recognition (37 C.F.R. 10.9 (b)) attached

Direct Dial Telephone: (650) 621-8581

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166

UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE



RECEIVED

AUG 06 2002

LIMITED RECOGNITION UNDER 37 CFR §10.9(b)


TECH CENTER 1600/2900

COPY OF PAGE  
ORIGINALLY FILED

Terrence Lo is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Incyte Pharmaceuticals, Inc. to prepare and prosecute patent applications wherein Incyte Pharmaceuticals, Inc. is the assignee of record of the entire interest in the application filed in the USPTO. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Terrence Lo ceases to lawfully reside in the United States; (ii) Terrence Lo's employment with Incyte Pharmaceuticals, Inc. ceases or is terminated; or (iii) Terrence Lo ceases to remain or reside in the United States on TN status.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: November 18, 2002

  
Harry I. Moatz  
Director of Enrollment and Discipline

RECEIVED

AUG 06 2002

TECH CENTER 1600/2900